Park Avenue Securities LLC Halozyme Therapeutics, Inc. Transaction History
Park Avenue Securities LLC
- $8.9 Billion
- Q3 2024
A detailed history of Park Avenue Securities LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Park Avenue Securities LLC holds 11,638 shares of HALO stock, worth $626,357. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,638
Previous 9,295
25.21%
Holding current value
$626,357
Previous $487,000
36.76%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding HALO
# of Institutions
492Shares Held
123MCall Options Held
208KPut Options Held
77.1K-
Black Rock Inc. New York, NY17.6MShares$948 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$693 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$313 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$217 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$200 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.5B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...